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Abstract
Background: We previously demonstrated oxymatrine, an alkaloid from the Chinese medicine radix Sophorae
flavescentis, ameliorates hemodynamic disturbances and cardiac fibrosis; however, the underlying mechanisms are
unclear. Here, we investigated the effect and mechanism of action of oxymatrine on aldosterone-induced cardiac
fibroblast to myofibroblast differentiation in vitro.
Methods: Cardiac fibroblasts were isolated purified from neonatal Sprague Dawley rats. The optimal concentration
of aldosterone to stimulate cardiac fibroblast proliferation was determined using the 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide (MTT) assay. Cardiac fibroblasts were pretreated with 7.57 × 10−4 mol/L or 3.78 × 10−4
mol/L oxymatrine or without oxymatrine for 2 h, and then coincubated with 1 × 10−8 mol/L aldosterone for 48 h.
The MTT assay and Masson staining were used to detect the cardiac fibroblast proliferation and myofibroblast
differentiation. The secretion of type I and III collagen was measured by commercial ELISA kits, and the hydroxyproline
content was determined by the colorimetric assay. Western blotting assayed the Smad-2, Smad-3, and Smad-4 protein
expression in cardiac fibroblasts.
Results: The present results confirmed that aldosterone induced cardiac fibroblast to myofibroblast proliferation and
differentiation. The MTT assay and Masson staining indicated oxymatrine significantly inhibited aldosterone-induced
cardiac fibroblast proliferation and myofibroblast differentiation. Oxymatrine significantly inhibited aldosterone-induced
secretion of type I and III collagen, as indicated by commercial ELISA kits, and aldosterone-induced increase in
hydroxyproline content, as indicated by a colorimetric assay. Western blotting revealed oxymatrine attenuated
aldosterone-induced Smad-2, Smad-3, and Smad-4 expression in cardiac fibroblasts.
Conclusion: Oxymatrine can inhibit cardiac fibroblast proliferation and differentiation into myofibroblasts via a
mechanism linked to attenuation of the Smad signaling pathway.
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Background
Cardiovascular diseases are a serious threat to health
and are the leading cause of death in humans [1, 2].
The mechanisms leading to cardiovascular diseases
and novel drug treatments have undergone intensive
research. It is well recognized that cardiac remodel-
ing, the final pathophysiological process of cardiovas-
cular diseases [3], is characterized by three phases:
cardiomyocyte hypertrophy and apoptosis, prolifera-
tion and differentiation of cardiac fibroblasts, and
extracellular matrix deposition. However, most drugs
in clinical application aim to prevent cardiomyocyte
hypertrophy and apoptosis, including angiotensin con-
verting enzyme inhibitors, beta-receptor blockers and
calcium antagonists. In fact, the key pathological
changes during cardiac remodeling involve cardiac
fibroblasts (CFs), especially CF differentiation into
myofibroblasts. The differentiation of CFs results in
increased secretion and deposition of myocardial col-
lagen, which induces myocardial stiffness and myocar-
dial diastolic and systolic dysfunction [4–6].
CFs are the main effector cells of cardiac remodeling
and can proliferate and differentiate into myofibroblasts,
and secrete extracellular matrix proteins such as type I
and III collagen [7, 8]. The pathological process of
cardiac remodeling involves a variety of factors, includ-
ing the rennin-angiotensin-aldosterone system (RAAS),
growth factor, transforming growth factor-β (TGF-β),
and nitric oxide, among others [9]. Accumulating evi-
dence indicates that TGF-β is the one of the key factors
that promotes CF differentiation, as direct blockade of
TGF-β expression decreases extracellular matrix depos-
ition and tissue fibrosis [10, 11]. Increased expression of
TGF-β1 and Smad2/3-Smad4 are positively associated
with deterioration of cardiac function after myocardial
infarction [12, 13]. The levels of CF-secreted endothelin
and TGF-β1 increase in cells treated with aldosterone
(ALD) [14].
Oxymatrine (OMT) is one of the main bioactive
ingredients of Kushen (Sophorae flavescentis radix)
which is a traditional Chinese herbal medicine made
from the dried root of S. flavescens Ait. (Fig. 1). Previous
data demonstrated that OMT exerts a wide-range of
pharmacological activities, such as anti-inflammatory,
anticancer, antiviral and immune regulation effects, and
it has been used to treat cardiovascular diseases [15].
Our previous study showed that OMT exerted an in-
hibitory effect in an experimental model of myocardial
fibrosis in rats induced by acute myocardial infarction,
via a mechanism involving the TGF-β-Smad signaling
pathway [16]. Zhang et al. recently reported that OMT
could ameliorate left ventricle hypertrophy and dys-
function in rats with heart failure [17]. Xiao and col-
leagues reported that OMT exerted a protective effect
against ALD-mediated cardiomyocyte injury [18].
Those evidences indicate that OMT can protect the
myocardium from apoptosis and fibrosis caused by a
variety of stimuli. Hence, the aim of the present study
was to further explore the ability of OMT to ameliorate
ALD-induced apoptosis in CFs. To the best of our
knowledge, this is the first demonstration that OMT




All animal experiments conformed to the Guide for the
Care and Use of Laboratory Animals published by
Guizhou Medical University and were approved by the
Bioethics Committee for Animal Studies of Guizhou
Medical University.
Materials
OMT (purity, 98 %) was purchased from Green Valley
Pharmaceutical Co. Ltd., Shanghai, China; ALD (purity,
98 %) was from Fluka, Switzerland; Trypsin was from
Solarbio, Beijing, China; Dulbecco’s modified Eagle’s
medium (DMEM) was from GIBCO, Gaithersburg,
USA; Penicillin and streptomycin were from Sigma, St.
Louis, MO, USA; ELISA assay kits were from Dize
Fig. 1 Chemical structure of oxymatrine (OMT)
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Bioengineering, Shanghai; Hydroxyproline assay kits
were obtained from Jiancheng Bioengineering, Nanjing,
China; and Smad-2,-3 and-4 antibodies were from Cell
Signaling Technology, Beverly, USA.
Isolation and culture of primary neonatal rat CFs
CFs were isolated and purified from 1- to 3-day-old
Sprague–Dawley rats. Briefly, the hearts of 1–3 day-old
Sprague Dawley rats were isolated and digested in
10 mL of phosphate buffered saline (PBS; 137 mM NaCl,
2.7 mM KCl, 10 mM Na2HPO4, 2 mM KH2PO4,
pH 7.2-7.4) containing 0.08 % trypsin for 10 min at
37 °C. After each digestion step, the medium contain-
ing suspended cells was removed and an equal
volume of Spinner/collagenase solution was added.
Primary cultures of rat cardiac stromal cells were
grown in DMEM supplemented with 20 % fetal bo-
vine serum, penicillin (100 U/mL) and streptomycin
(100 U/mL) at 37 °C in a humidified atmosphere of
5 % CO2. CFs at the third or fourth passage was used
for experiments. The seeding density was 1 × 105
cells/mL for the MTT assay and morphological ana-
lyses and 2 × 105 cells/mL for Western blot analysis.
The purity of the neonatal rat CF cultures was about
99 %, as indicated by vimentin immunocytochemical
staining.
CF proliferation assay
CFs cultured in 96-well plates were exposed to ALD
(1 × 10−8 M) alone for 48 h or pretreated with different
concentrations of OMT (3.78 × 10−4 M to 7.57 × 10−4 M)
for 2 h before exposure to ALD for 48 h. Then, 3-(4,5-
dimethyl-thiazol-2-yl)-2,5-diphenyltetrazolium bromide
(MTT) was added to each well (final concentration
0.5 mg/mL) in sterile conditions, and the plates were in-
cubated for 4 h at 37 °C in a 5 % CO2 incubator, finally
the medium was discarded and washed 3 times with
PBS. Formazan salt crystals were dissolved by addition
of 150 μL dimethylsulfoxide per well and the absorbance
values were determined at 490 nm using a microplate
reader (ELX800; GE, USA).
Enzyme-linked immunosorbent assay (ELISA)
The levels of type I and III collagen in the cell lysis buf-
fer and cell supernatants were measured using ELISA
assay kits. The OD values were measured at 450 nm
using an ELX800 microplate reader.
Hydroxyproline colorimetric assay
The hydroxyproline (Hyp) content of the cell lysis
buffer and cell supernatants was quantified using a
commercial Hyp detection kit. The OD values of the
samples were measured at 550 nm using an ELX800
microplate reader.
Western blotting
Western blotting assays were used to measure the
protein expression levels of Smad-2,-3,-4, and β-actin
in CFs. After treatment, CFs were washed once in
ice-cold PBS, and then lysed in lysis buffer (Dingguo,
Beijing, China) on ice. Protein concentrations were
assessed using a bicinchoninic acid protein assay kit
(Dingguo, Beijing, China). Equal amounts of protein
were subjected to 12 % SDS-polyacrylamide gel elec-
trophoresis, transferred onto PVDF membranes using
a Bio-Rad Western blot analysis apparatus, and then
the membranes were blocked in 5 % non-fat dry milk
in TBST, then incubated with primary Smad-2,-3,-4
(1:1000 dilution), and β-actin (1:1000; Cell Signaling
Fig. 2 Inhibitory effect of OMT on ALD-induced cardiac fibroblast
proliferation. Cardiac fibroblasts were pretreated with 7.57 × 10−4
mol/L [High] or 3.78 × 10−4 mol/L [Low] OMT or without OMT for
2 h, and then coincubated with ALD (1 × 10−8 mol/L) for 46 h. a Cell
viability was determined using the MTT assay. b Collagen fibers were
visualized using Masson staining. Representative images of collagen
fibers (green or blue), myocardial fibers (red), erythrocytes (orange),
and nuclei (blue): (i) Control; (ii) ALD; (iii) OMT (Low); (iv) OMT (High).
Results are means ± SEM of three independent experiments (*P <
0.05, **P < 0.01 vs. control group; #P < 0.05, ##P < 0.01 vs. ALD
alone, n = 5)
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Technology) antibodies overnight at 4 °C. After wash-
ing three times with TBST, the membranes were incu-
bated with the corresponding secondary antibodies
(1:4000, Sigma, MS, USA) for 2 h at room
temperature, and the immunolabeled bands were
visualized using Pierce ECL Western blotting sub-
strate (Millipore, Bedford, USA).
Statistical analysis
All data are presented as the mean ± SEM. Between-
group comparisons were performed using t-tests. All
data analysis was performed using Microsoft Excel. Stat-
istical significance was defined as P < 0.05; P < 0.01 was
considered highly significant.
Results
OMT inhibits ALD-induced CF proliferation and
differentiation
The MTT assay and Masson staining were used to
assess the ability of OMT to inhibit ALD-induced
CF proliferation and differentiation. CFs were pre-
treated with or without different concentrations of
OMT (3.78 × 10−4 M and 7.57 × 10−4 M) for 2 h and
then stimulated with ALD (1 × 10−8 M) for 24 h.
The MTT assay showed that ALD significantly in-
creased CF proliferation compared to control cells.
However, pretreatment with OMT inhibited the
ALD-induced increase in CF proliferation (Fig. 2a).
CF differentiation was also investigated using Mas-
son staining (Fig. 2b). ALD increased CFs differenti-
ation to myofibroblasts and collagen deposition
compared to control cells; however, OMT signifi-
cantly ameliorated ALD-induced CF differentiation
and collagen deposition.
OMT attenuates ALD-induced type collagen I and colla-
gen III deposition in CFs
Type I and III collagen are the key biomarkers of CFs
differentiation into myofibroblasts. ELISAs were used
to assess the secretion of type I and III collagen. Ex-
posure of CFs to ALD significantly increased the
levels of type I and III collagen in the cell lysis buffer
and cell supernatant compared to control cells
(Fig. 3a-d). However, pretreatment with OMT attenu-
ated the ALD-induced increases in the levels of type I
and III collagen in the cell lysis buffer and cell super-
natant (Fig. 3a-d).
OMT inhibits ALD-induced hydroxyproline secretion
by CFs
Hyp, a degradation production of collagen, repre-
sents an index of collagen secretion which, to an
Fig. 3 Inhibitory effects of OMT on ALD-induced type I and III collagen secretion of cardiac fibroblasts. Cardiac fibroblasts were pre-treated with
7.57 × 10−4 mol/L [High] or 3.78 × 10−4 mol/L [Low] OMT or without OMT for 2 h, and then coincubated with ALD (1 × 10−8 mol/L) for 46 h. a
ELISA assays of type I collagen content in cell lysis buffer; (b) type III collagen content in cell lysis buffer; (c) type I collagen content in cell
supernatant; and (d) type III collagen content in cell supernatant. Results are means ± SEM of three independent experiments. (*P < 0.05, **P < 0.01 vs.
control cells; #P < 0.05, ##P < 0.01 vs. ALD alone, n = 5)
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extent, can reflect myofibroblast secretion activity.
Hyp was measured using a commercial colorimetric
assay. ALD increased the Hyp content of the cell
lysis buffer and cell supernatant of cultured CFs
(Fig. 4a-b). Compared to cells treated with ALD, pre-
treatment with OMT significantly reduced the ALD-
induced increase in the Hyp content of the cell lysis
buffer and cell supernatant (Fig. 4a-b).
OMT inhibits ALD-induced expression of smad-2,-3, and-4
in CFs
The TGF-β-Smad signaling pathway provides the stron-
gest activation signal for organic fibrosis; Smad-2,-3,
and-4 are key factors in this signaling pathway. There-
fore, we explored Smads protein expression in CFs ex-
posed to ALD. Western blotting showed that ALD
enhanced the expression of Smad-2,-3, and-4 in CFs
(Fig. 5a-c) compared to control cells. Pretreatment with
OMT attenuated the ALD-induced increases in Smad-2,-
3, and-4 protein expressions in CFs.
Discussion
Chronic heart failure is a pathological process caused by
cardiac remodeling events, including myocardial hyper-
trophy, myocardial cell loss, and myocardial fibrosis
(MF) [19–21]. Clinical data have confirmed MF occurs
as an inevitable process during the progression of heart
disease to its terminal stage and the key factors of car-
diac function by compensatory period to decompensa-
tion period [22, 23]. Therefore, inhibition of abnormal
cardiac remodeling, the reaction to target organ damage
and fibrosis, by reversing a variety of chronic inflamma-
tory reactions, may represent a primary treatment
strategy to improve clinical outcomes and reduce mor-
tality in patients with chronic heart failure [24].
It has been confirmed that the RAAS is a key signal
transduction pathway involved in organic fibrosis.
Recent reports have indicated that ALD, the final mol-
ecule of the RAAS pathway, is widely implicated in myo-
cardial fibrosis and promotes the synthesis of collagen in
cardiac CFs [25–28]. In this study, to contribute to the
development of novel therapeutic strategies for treating
cardiovascular disease, we investigated the ability of
OMT to inhibit ALD-induced CF proliferation and
differentiation in vitro and explored the associated
mechanisms.
The MTT assay showed that CFs exposed to 1 × 10−8
mol/L ALD alone for 48 h displayed significantly higher
levels of proliferation (P < 0.01) compared with control
cells. However, pretreatment with OMT significantly at-
tenuated ALD-induced cell proliferation. Masson stain-
ing confirmed that OMT significantly reduced ALD-
induced collagen fiber accumulation in CFs, and ELISAs
suggested that OMT inhibited the ALD-induced secre-
tion of type I collagen, type III collagen and Hyp.
Smad-2,-3, and-4, and the TGF-β1-Smads pathway
are implicated in fibrosis. Activation of TGF-β1-
Smads is an important signal that leads to cardiac fi-
brosis. Western blotting showed ALD significantly
increased the expression of Smad-2,-3, and-4; these
three proteins can promote myocardial fibrosis and
play major roles in the TGF-β-Smad signaling path-
way. However, OMT significantly inhibited ALD-
induced protein expression of Smad-2,-3 and-4 com-
pared to cells treated with ALD alone. These results
suggest that OMT may inhibit ALD-induced prolifer-
ation and differentiation of CFs via a mechanism
linked to the TGF-β/Smad signaling pathway and
downregulation of Smad-2,-3 and-4 protein expres-
sion. The potential of OMT as a drug to prevent
and treat MF merits further research in preclinical
models.
Fig. 4 Inhibitory effect of OMT on ALD-induced hydroxyproline
(Hyp) secretion by cardiac fibroblasts. Cardiac fibroblasts were
pre-treated with 7.57 × 10−4 mol/L [High] or 3.78 × 10−4 mol/L
[Low] OMT or without OMT for 2 h, and then coincubated
with ALD (1 × 10−8 mol/L) for 46 h. a Analysis of hydroxypro-
line content in cell lysis buffer and (b) cell supernatant.
Results are means ± SEM of three independent experiments.
(*P < 0.05, **P < 0.01 vs. control cells; #P < 0.05, ##P < 0.01 vs.
ALD alone, n = 4)
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Conclusion
OMT attenuates ALD-induced CF proliferation and
differentiation into myofibroblasts via a mechanism that
involves the TGF-β-Smad signal transduction pathway.
The present study highlights on a novel molecular
mechanism by which OMT inhibits ALD-induced CF
differentiation into myofibroblasts.
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Fig. 5 Inhibitory effect of OMT on ALD-induced expression of Smad-2,-3, and-4 in cardiac fibroblasts. Cardiac fibroblasts were pretreated with
7.57 × 10−4 mol/L [High] or 3.78 × 10−4 mol/L [Low] OMT or without OMT for 2 h, and then coincubated with ALD (1 × 10−8 mol/L) for 46 h.
Western blotting analysis of (a) Smad-2, (b) Smad-3 and (c) Smad-4. Results are means ± SEM of three independent experiments.
(*P < 0.05, **P < 0.01 vs. control cells; #P < 0.05, ##P < 0.01 vs. ALD alone, n = 4)
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